ArticleMethods in molecular biology (Clifton, N.J.)2012
Fate tracing of neurogenin2-expressing cells in the mouse retina using CreER™: LacZ.
Article in Methods in molecular biology (Clifton, N.J.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Delineating the final fate of progenitor cells that transiently express a regulatory gene may shed light on how the gene participates in regulating retinal development. We describe the steps in tracing final fates of progenitor cells that once transiently express neurogenin2 (ngn2) during mouse retinal development with the binary, conditional Ngn2-CreER(™)-LacZ reporter system. Ngn2-CreER(™) mice (Zirlinger et al. Proc Natl Acad Sci USA 99:8084-8089, 2002), in which ngn2 promoter drives the expression of Cre-estrogen receptor CreER(™) (Littlewood et al. Nuc Acid Res 23:1686-1690, 1995; Hayashi and McMahon Dev Biol 244:305-318, 2002), are crossed with Rosa26-LoxP-LacZ reporter mice (Soriano Nat Genet 21:70-71, 1999), in which the expression of lacZ requires the removal of "stop" by Cre recombinase (Wagner et al. Transgenic Res 10:545-553, 2001). 4-hydroxytamoxifen (4-OHT), a synthetic ligand with high affinity for ER(™), is administered to double transgenic embryos and/or neonatal mice. Binding of 4-OHT to Cre-ER(™) activates Cre recombinase, which then catalyzes the removal of the "stop" sequence from the LoxP-LacZ transgene, leading to lacZ expression in cells that express ngn2. Retinal tissues are fixed at different time points after 4-OHT treatment and analyzed for LacZ activities by colorimetric reaction. Double-labeling with a cell type-specific marker can be used to define the identity of a LacZ(+) cell. Combining persisted lacZ expression through the life of the cell and the short half-life (0.5-2 h) of 4-OHT (Danielian et al. Curr Biol 8:1323-1326, 1998), this system offers the opportunity to track the final fates of cells that have expressed ngn2 during the brief presence of 4-OHT administered during retinal development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.